STAT15h
U.K. lawmaker wants regulators to probe pharma companies over ‘misleading’ Covid-19 vaccines statements
A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...
Fact Check: Moderna began clinical trials of COVID vaccine in 2020, not 2017
Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
FierceBiotech21h
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Moderna Stock Falls on Earnings Report. The Results Reaffirm a Grim Picture for Vaccine Maker.
Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...
FiercePharma7h
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Yahoo Finance12d
Pfizer and Moderna’s parent are investing $100 million in a new partnership to find the next big drug
in the effort to create a vaccine. Will their partnership lead to a new model for drug development that accelerates medical innovation? Here’s Afeyan again: ...
Could Moderna’s (MRNA) 65% Stock Plunge Entice a Takeover?
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
What Investors Are Missing about Pfizer and Merck
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
Moderna Stock Falls After Vaccine Maker Posts Wider-Than-Expected Loss
Moderna shares fell 3% in premarket trading after the biotech company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, ...